Metamizol Kalceks

Metamizole sodium monohydrate, the active ingredient in Metamizol Kalceks, is a pyrazolone presented as an injectable solution for intramuscular and intravenous use. It treats moderate to severe pain and fever in adult patients.

GNH USA supplies Metamizol Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizole sodium is an analgesic/antipyretic that reduces pain and fever by inhibiting prostaglandin synthesis.

- Pain (moderate to severe): provides rapid analgesia for acute, postoperative or traumatic pain. - Fever: lowers elevated body temperature in febrile conditions. - Post‑surgical discomfort: helps control pain after surgical procedures.

Metamizole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site pain: discomfort at the site of intramuscular or intravenous administration. - Hypotension: transient lowering of blood pressure, especially with rapid IV infusion. - Nausea: mild gastrointestinal upset. - Dizziness: sensation of light‑headedness or vertigo.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction of white blood cells, requiring immediate medical attention. - Anaphylactic reaction: sudden, life‑threatening allergic response. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hemolytic anemia: destruction of red blood cells leading to anemia.

Metamizol should be used with careful clinical assessment and monitoring.

- Renal function: assess kidney status and adjust use in patients with renal impairment. - Hepatic function: exercise caution in liver disease due to altered metabolism. - Hematologic monitoring: obtain baseline blood counts and monitor for agranulocytosis. - Allergy history: avoid in individuals with known hypersensitivity to pyrazolones. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Metamizol can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Concurrent myelosuppressive agents: increased risk of agranulocytosis. - Other NSAIDs: additive gastrointestinal and renal toxicity. - ACE inhibitors: may potentiate hypotensive effects. - Anticoagulants: heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Carbamazepine: enzyme induction may reduce metamizole efficacy. - Lithium: possible elevation of lithium serum levels. - Warfarin: monitor INR for anticoagulant effect changes.